x

Search for a networks

* (*) mandatory field

A Randomized, Double-blind, Placebo-controlled, Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Primary Immune Thrombocytopenia

  • Type of network : Multinational clinical trials
  • Geographic coverage : European
  • Funding body(ies) : ARGENX BVBA 
  • Sponsor : Information not provided
  • Website
  • Coordinator of multinational clinical trial

  • INFORMATION NOT PROVIDED
  • Institution: Information not provided - BE
  • ADDRESS: NOT PROVIDED - BE
  • BELGIUM
  • More information
  • Phone  : -
  • Fax  : -
Last update: October 2018

Additional information

The documents contained in this web site are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.